CARPALL
Immunotherapy with CD19/22 CAR redirected T-cells for high risk/relapsed paediatric CD19+ and / or CD22+ acute lymphoblastic leukaemia and other haematological malignancies
A multi-centre, non-randomised, open label phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults with high risk, relapsed CD19+ and/or CD [...]
Area:
Advanced therapies
Phase:
Phase I
Status:
In follow-up (non-recruiting)